



NovaSecta is an R&D Services Business for Mid-sized Pharmaceutical and Biotech Companies ('MidPharmas')

Connections, Intelligence & Consulting Services

We create connections and collaborations for MidPharmas
We maintain unique and authoritative intelligence on MidPharma R&D
We partner with MidPharmas to implement their R&D strategies

Research & Development Solutions

With strategic alliance partners, we deliver R&D outcomes for MidPharmas in discovery, chemical/pharmaceutical development and clinical development

HD Biosciences



HD Biosciences

Sundia Meditech



Tigermed Consulting



Connections, Intelligence & Consulting Services

Our 'MidPharma R&D Program' provides practical insights, ideas and options for how to structure and operate highly productive R&D at a mid-sized scale

- A unique Community of Practice for R&D managers of a group of mid-sized pharmaceutical and biotech companies, now in its third year
- Business research, analysis and benchmarking of private and public data concerning R&D strategies and operations of MidPharmas; customized management workshops; interactive meetings with peers to discuss R&D issues and experiences

Our annual 'Pharma Network' meeting connects and informs MidPharma corporate leaders

- An annual private by-invitation annual summit meeting solely for CEOs and Executive Board members of European MidPharmas, now in its sixth year
- Interactive case-study discussions of core issues facing companies in the sector

We partner with MidPharmas to implement their R&D strategies, for example:

- We valued and positioned a MidPharma's core R&D assets, connected the company with suitable co-development partners, and supported deal negotiations
- We developed a comprehensive and implementable new Discovery Research operational model and structure to implement a MidPharma's new R&D strategy

R&D Solutions

With strategic alliance partners, we deliver R&D outcomes in discovery, chemical/pharmaceutical development and clinical development



Discovery

- Medicinal chemistry, organic synthesis, parallel synthesis
- Assay development and validation
- HTS/MTS, follow-up hit confirmation, selectivity profiling
- Non-GLP *in vitro* and *in vivo* pharmacology and ADMET
- Preformulation, drug characterization and evaluation

Chemical/Pharmaceutical Development for FDA/EMEA

- Process chemistry, including chiral technology
- Formulation and analytical method development
- GMP scale-up and clinical trial supply

Clinical Development in China

- GCP trials in China for global Phase I-IV trials
- Chinese registration of products already launched in the West
- Clinical proof-of-concept or first market launch in indications where Western patients are scarce

Our team members have practical experience in the pharma, biotech and consulting industries

NovaSecta is led by co-founders John Rountree and Robert Thong

John Rountree	Robert Thong
<p>Prior to founding NovaSecta, John's roles included:</p> <ul style="list-style-type: none">• Head of European Operations, Integral Inc• Senior Partner, Strategic Decisions Group Inc• Principal, Deloitte Haskins & Sells <p>John was educated at Brasenose College, Oxford University (MA Engineering, Economics and Management) and the London Business School (MBA)</p>	<p>Prior to founding NovaSecta, Robert's roles included:</p> <ul style="list-style-type: none">• Managing Director, Datamonitor Healthcare• Non-executive Board Director, Alpha Pharma Inc• Founder/CEO, Phizz Rx• Senior Vice President, Gemini Consulting Life Sciences Group <p>Robert was educated at Imperial College, University of London (BSc Mathematics) and the MIT Sloan School of Management (MBA)</p>